Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
Michael Marcus, MD, Stony Brook University Health Sciences Center, Stony Brook, NY, discusses the difference between the common cold and allergies in pediatric patients. Submitted by: Dr. Melvin…
Greg Foltz, MD, Director, Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, Washington, discusses the Center for Advanced Brain Tumor Treatment. For more information visit: Center…
Greg Foltz, MD, Director, Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA, discusses current treatments for brain cancer. References and Resources Schönekaes K, Mücke R,…
A feasibility study presented at the American Association for Cancer Research meeting showed that intraductal chemotherapy may have potential as a treatment for ductal carcinoma in situ and…
Bill Crounse, MD, Senior Director for Worldwide Health, Microsoft Corporation, discusses the need and importance of The Doctor’s Channel, and applauds its unique concept. For the Bill Crounse,…
Bill Crounse, MD, Senior Director for Worldwide Health, Microsoft Corporation, discusses patients and their increasing use of the internet for health information. For the Bill Crounse, MD blog…
Bill Crounse, MD, Senior Director for Worldwide Health, Microsoft Corporation, discusses how Health Vault refines the experience of managing personal health for consumers. For the Bill Crounse, MD…
Howard (Jack) West, MD, Medical Director, Thoracic Oncology Program Swedish Cancer Institute, President & CEO, Global Resource for Advancing Cancer Education (GRACE), Seattle, WA, discusses lung cancer in…
A study presented at the American Association for Cancer Research meeting showed progression of androgen-independent prostate cancer was significantly inhibited in mice by a combination of atorvastatin (Lipitor)…
Rituximab failed to meet the primary endpoint of stemming the progression of primary-progressive multiple sclerosis (PPMS) in a Phase II/III trial. From Our Partners at VerusMed verusmed.com Sponsored…
